僅用于工業應用或科學研究，不可用于人類或動物的臨床診斷或治療，非藥用. Monalizumab （IPH2201） is an immune checkpoint inhibitor targeting Natural Killer Group 2A （NKG2A）. Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma （HNSCC）